Gynipral (Hexoprenaline Sulfate)

Gynipral is a prescription medication that contains the active ingredient hexoprenaline sulfate, supplied as an intravenous solution. It belongs to the beta‑2 adrenergic agonist class and is used primarily as a tocolytic agent to manage uterine activity. The product is marketed in the European Union and is administered under medical supervision. The formulation does not contain additional excipients that alter its pharmacologic profile, and dosing is individualized based on clinical assessment.

Gynipral is indicated for situations where suppression of uterine contractions is clinically required.

- Management of preterm labor to delay delivery. - Treatment of uterine tachysystole during labor induction. - Adjunct therapy in obstetric procedures requiring uterine relaxation. - Short‑term use when rapid inhibition of uterine activity is needed. - Off‑label use may include experimental protocols under research settings.

The safety profile of Gynipral includes both frequently observed and less common adverse reactions.

Common: - Tremor or shaking. - Palpitations or increased heart rate. - Nausea.

Serious: - Significant arrhythmias. - Severe hypotension. - Allergic reactions including rash or anaphylaxis.

When prescribing Gynipral, clinicians should evaluate patient history and monitor specific parameters to minimize risk.

- Use only under continuous cardiac and fetal monitoring. - Contraindicated in patients with known hypersensitivity to hexoprenaline or related beta‑2 agonists. - Caution in individuals with cardiovascular disease, especially arrhythmias or hypertension. - Avoid in uncontrolled hyperthyroidism. - Assess blood glucose in diabetic patients, as beta‑2 stimulation may affect glycemic control. - Limit duration of therapy to the shortest effective period.

Gynipral may interact with other medications that influence cardiovascular or smooth‑muscle function.

Avoid: - Concurrent use with non‑selective beta‑blockers, which can diminish tocolytic effect. - Combination with other potent vasodilators, increasing risk of hypotension.

Use with caution: - Concurrent administration of other beta‑2 agonists (e.g., terbutaline) may enhance side‑effects. - Drugs that affect electrolyte balance, such as diuretics, may increase risk of cardiac arrhythmias. - Anticoagulants, because uterine relaxation may alter bleeding risk.